Hanmi Pharm Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Hanmi Pharm kazanç ve gelirin sırasıyla yıllık 6.2% ve 7.5% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 6% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 15.5% olacağı tahmin edilmektedir.

Anahtar bilgiler

6.2%

Kazanç büyüme oranı

6.0%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	33.3%
Gelir büyüme oranı	7.5%
Gelecekteki özkaynak getirisi	15.5%
Analist kapsamı	Good
Son güncelleme	21 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Hanmi Pharm. Co., Ltd. (KRX:128940)

Nov 19

Does Hanmi Pharm (KRX:128940) Have A Healthy Balance Sheet?

Nov 01

Does Hanmi Pharm (KRX:128940) Deserve A Spot On Your Watchlist?

Oct 17

Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 36% Below Their Intrinsic Value Estimate

Aug 16

Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 22% Below Their Intrinsic Value Estimate

Nov 24

Kazanç ve Gelir Büyüme Tahminleri

KOSE:A128940 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (KRW Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	1,873,608	210,514	250,226	300,764	16
12/31/2025	1,738,424	187,472	227,007	280,653	17
12/31/2024	1,589,127	163,720	253,901	289,507	13
6/30/2024	1,568,781	184,377	198,396	253,078	N/A
3/31/2024	1,533,383	158,086	215,064	266,810	N/A
12/31/2023	1,490,887	146,231	173,029	216,538	N/A
9/30/2023	1,419,708	131,316	93,449	133,068	N/A
6/30/2023	1,397,244	101,982	98,900	139,958	N/A
3/31/2023	1,371,607	106,424	100,087	142,458	N/A
12/31/2022	1,331,547	82,792	111,618	162,269	N/A
9/30/2022	1,330,854	80,780	212,242	258,668	N/A
6/30/2022	1,291,788	78,807	222,898	267,987	N/A
3/31/2022	1,253,997	67,497	242,072	281,103	N/A
12/31/2021	1,203,186	67,025	167,776	201,923	N/A
9/30/2021	1,130,015	77,337	186,309	227,481	N/A
6/30/2021	1,093,865	23,092	145,080	185,482	N/A
3/31/2021	1,057,969	23,462	92,160	139,157	N/A
12/31/2020	1,075,854	11,959	93,785	151,535	N/A
9/30/2020	1,101,450	-1,238	27,417	114,463	N/A
6/30/2020	1,100,225	36,049	-15,536	121,852	N/A
3/31/2020	1,127,208	46,907	-118,323	64,277	N/A
12/31/2019	1,113,650	52,110	-165,540	12,447	N/A
9/30/2019	1,104,465	29,815	-151,837	52,148	N/A
6/30/2019	1,074,014	34,892	-178,529	11,181	N/A
3/31/2019	1,044,929	29,971	-167,121	54,106	N/A
12/31/2018	1,015,962	24,891	-184,829	25,982	N/A
9/30/2018	954,879	41,003	-253,511	-57,022	N/A
6/30/2018	947,203	50,120	-286,240	-61,733	N/A
3/31/2018	928,713	49,170	N/A	-58,807	N/A
12/31/2017	916,586	60,434	N/A	-62,905	N/A
9/30/2017	856,033	12,415	N/A	-499	N/A
6/30/2017	848,177	-3,433	N/A	8,921	N/A
3/31/2017	859,901	4,177	N/A	3,461	N/A
12/31/2016	882,725	23,326	N/A	412,965	N/A
9/30/2016	1,300,579	220,192	N/A	473,881	N/A
6/30/2016	1,349,235	188,682	N/A	439,648	N/A
3/31/2016	1,359,164	179,858	N/A	464,276	N/A
12/31/2015	1,317,535	154,443	N/A	101,712	N/A
9/30/2015	939,070	9,750	N/A	-35,497	N/A
6/30/2015	850,027	37,587	N/A	1,946	N/A
3/31/2015	791,905	33,760	N/A	-35,048	N/A
12/31/2014	761,280	35,510	N/A	-32,820	N/A
9/30/2014	743,779	32,302	N/A	-9,178	N/A
6/30/2014	750,634	45,249	N/A	16,754	N/A
3/31/2014	743,951	45,870	N/A	56,428	N/A
12/31/2013	730,134	43,933	N/A	85,992	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: A128940 'nin tahmini kazanç büyümesi (yıllık 6.2% ) tasarruf oranının ( 2.7% ) üzerindedir.

Kazançlar ve Piyasa: A128940 şirketinin kazançlarının (yıllık 6.2% ) KR pazarından (yıllık 28% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: A128940 şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: A128940 şirketinin gelirinin (yıllık 7.5% ) KR pazarından (yıllık 9.4% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: A128940 şirketinin gelirinin (yıllık 7.5% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: A128940 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 15.5 %).

Hanmi Pharm Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates increase by 10%

Consensus EPS estimates increase by 10%

Consensus EPS estimates fall by 12%

Consensus EPS estimates increase by 24%

Consensus EPS estimates increase by 13%

Consensus forecasts updated

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Hanmi Pharm. Co., Ltd. (KRX:128940)

Investor sentiment deteriorates as stock falls 16%

Does Hanmi Pharm (KRX:128940) Have A Healthy Balance Sheet?

Hanmi Pharm. Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Does Hanmi Pharm (KRX:128940) Deserve A Spot On Your Watchlist?

GC Biopharma and Hanmi Pharmaceutical Receives IND Clearance for Phase 1/2 Clinical Trial from the U.S. FDA

Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 36% Below Their Intrinsic Value Estimate

Pinning Down Hanmi Pharm. Co., Ltd.'s (KRX:128940) P/E Is Difficult Right Now

Hanmi Pharm. Co., Ltd. to Report First Half, 2024 Results on Jul 30, 2024

Do Hanmi Pharm's (KRX:128940) Earnings Warrant Your Attention?

Hanmi Pharm (KRX:128940) Seems To Use Debt Rather Sparingly

Now 23% undervalued after recent price drop

Now 20% undervalued after recent price drop

A Look At The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)

Consensus EPS estimates increase by 10%

Hanmi Pharm. Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Hanmi Pharm. Co., Ltd.'s (KRX:128940) Share Price Not Quite Adding Up

Now 21% undervalued after recent price drop

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Now 22% undervalued

New minor risk - Shareholder dilution

Hanmi Pharm. Co., Ltd. to Report Q4, 2023 Results on Feb 02, 2024

Upcoming dividend of ₩490 per share at 0.2% yield

Consensus EPS estimates increase by 10%

Hanmi Pharm. Co., Ltd. to Report Q3, 2023 Results on Nov 01, 2023

Investor sentiment improves as stock rises 20%

Assertio Holdings, Inc. (NasdaqCM : ASRT) completed the acquisition of Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI).

Consensus EPS estimates fall by 12%

Hanmi Pharm. Co., Ltd. to Report Q2, 2023 Results on Jul 28, 2023

First quarter 2023 earnings released: EPS: ₩3,467 (vs ₩1,566 in 1Q 2022)

Consensus EPS estimates increase by 24%

Investor sentiment improves as stock rises 19%

Full year 2022 earnings: EPS exceeds analyst expectations

Upcoming dividend of ₩490 per share

Less than half of directors are independent

Consensus EPS estimates increase by 13%

Now 25% undervalued after recent price drop

Consensus forecasts updated

Consensus EPS estimates increase by 28%

Less than half of directors are independent

Now 22% undervalued

Upcoming dividend of ₩490 per share

Hanmi Pharmaceutical Finds New Innovative Potential for Efpeglenatide

Price target increased to ₩385,044

Calculating The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)

Hanmi Pharm. Co., Ltd., Annual General Meeting, Mar 26, 2021

New 90-day low: ₩319,000

Hanmi Pharm (KRX:128940) Use Of Debt Could Be Considered Risky

New 90-day high: ₩405,000

What Percentage Of Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Do Insiders Own?

New 90-day high: ₩394,000

Hanmi Pharm's (KRX:128940) Stock Price Has Reduced 48% In The Past Five Years

New 90-day high: ₩375,000

Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 22% Below Their Intrinsic Value Estimate

New 90-day high: ₩327,500

Analysts lower EPS estimates to ₩2,279

Analysts update estimates

Price target raised to ₩342,471

New 90-day high - ₩284,500

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin